ACTRN12605000375651
Completed
Phase 1
Phase I/II study to find the maximum tolerable dose of the combination of capecitabine and oral cyclophosphamide in the treatment of advanced cancer
Dr Michael Findlay0 sites40 target enrollmentSeptember 13, 2005
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Advanced Cancer
- Sponsor
- Dr Michael Findlay
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological / cytological evidence of carcinoma; performance status (WHO) 0\-2; adequate bone marrow, renal and hepatic function;recovery from prior chemotherapy toxicity and calculated creatine clearance \>50ml/min.
Exclusion Criteria
- •Lack of physical integrity of upper GI tract; more than 2 prior courses of chemotherapy; prior pelvic radiation; pregnant or lactating; investigational drug within 4 weeks; history of clinically significant cardiac disease or MI in past 12 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphomaISRCTN42054893niversity of Birmingham (UK)58
Active, not recruiting
Phase 1
A phase I/II study to find the safe dose of the combination of romidepsin and carfilzomib (phase I) in patients with relapsed or refractory T-Cell lymphoma. The phase II part of the study will look at the activity of the combination.Peripheral T-cell LymphomaMedDRA version: 20.0Level: PTClassification code 10034626Term: Peripheral T-cell lymphoma unspecified refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034625Term: Peripheral T-cell lymphoma unspecified recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001879-20-GBniversity of Birmingham57
Withdrawn
Not Applicable
A phase I study to determine the maximum tolerable dose (MTD) of weekly carboplatin with the Wee1 inhibitor AZD1775 in patients with p53 mutated solid tumors.NL-OMON45937Antoni van Leeuwenhoek Ziekenhuis30
Recruiting
Not Applicable
Phase 1 study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, and efficacy of AVI-3207 Inj. in patients with neovascular age-related macular degeneratioDiseases of the eye and adnexaKCT0004887Avixgen9
Completed
Phase 1
A Phase I Study of LBH589 in Children With Refractory Solid and Central Nervous System (CNS) TumoursACTRN12609000978268Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)52